Literature DB >> 2105175

Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model.

J K Mickelson1, P J Simpson, M Cronin, J W Homeister, E Laywell, J Kitzen, B R Lucchesi.   

Abstract

Coronary artery rethrombosis can complicate initially effective thrombolytic therapy. Platelets interacting with injured vascular endothelium in a region along the coronary artery with reduced luminal cross-sectional area contribute to rethrombosis. The purpose of this study was to investigate the potential of the F(ab')2 fragment of the murine monoclonal antibody 7E3 [7E3 F(ab')2] to prevent rethrombosis after intracoronary clot lysis with recombinant tissue-type plasminogen activator (rt-PA) in an experimental model. The 7E3 F(ab')2 binds to the platelet glycoprotein IIb/IIIa complex (GPIIb/IIIa), thereby preventing platelet-fibrinogen interaction and intravascular thrombus formation. Experimental coronary artery thrombosis was produced in the anesthetized dog by application of direct anodal current to the intimal surface of the left circumflex coronary artery in the region of an external stenosis. Lysis of the established intracoronary thrombus was achieved with the intravenous administration of rt-PA (25 mg) after which the animals were randomized into two groups. Group 1 (n = 10) served as the control, receiving the saline diluent, and group 2 (n = 9) received 7E3 F(ab')2, given as a single intravenous injection (0.8 mg/kg). The times required for occlusive thrombus formation, rt-PA-induced thrombolysis, and rethrombosis (if it occurred) were similar in the animals treated with saline and those treated with 7E3 F(ab')2. The initial left circumflex coronary artery blood flow was similar in both groups but decreased to a negligible level in group 1. In group 2, left circumflex coronary artery blood flow declined modestly (24 +/- 2 to 10 +/- 2 ml/min). Rethrombosis occurred in all animals in group 1 but in only two of nine animals in group 2 (p less than 0.05). Oscillations in coronary blood flow preceded rethrombosis in group 1, whereas 7E3 F(ab')2 stabilized left circumflex coronary artery blood flow patterns during the course of teh experimental protocol (5.2 +/- 0.9 vs. 0.7 +/- 0.4 oscillations, respectively; p less than 0.05). Thrombus mass recovered from the left circumflex coronary artery at the conclusion of each experiment was greater in group 1 as compared with group 2 (7.0 +/- 2.3 vs. 1.5 +/- 0.7 mg, respectively; p less than 0.05). The area of left ventricle at risk for infarction was similar in both groups but infarct size, infarction/at risk assessed histochemically, was larger in group 1 than group 2 (35 +/- 9% vs. 6 +/- 4%, respectively; p less than 0.05). Platelet aggregation induced by ADP and arachidonic acid was similar at baseline for all of the animals.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2105175     DOI: 10.1161/01.cir.81.2.617

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

Review 1.  Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction.

Authors:  M P Hudson; A B Greenbaum; R A Harrington; E M Ohman
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

Review 2.  Integrins.

Authors:  E Ruoslahti
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

3.  Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.

Authors:  D J Fitzgerald; M Hanson; G A FitzGerald
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

4.  Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796.

Authors:  James K Hennan; Ting-Ting Hong; David E Willens; Edward M Driscoll; Thierry A Giboulot; Benedict R Lucchesi
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

5.  Tetrafibricin, a novel non-peptide fibrinogen receptor antagonist, induces conformational changes in glycoprotein IIb/IIIa.

Authors:  T Satoh; W C Kouns; Y Yamashita; T Kamiyama; B Steiner
Journal:  Biochem J       Date:  1994-08-01       Impact factor: 3.857

6.  Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist.

Authors:  B R Lucchessi; W E Rote; E M Driscoll; D X Mu
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

Review 7.  Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease.

Authors:  D Faulds; E M Sorkin
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.